Shandong Xinhua Pharmaceutical's (HKG:0719, SHE:000756) marketing application for pentazocine has been approved by China's National Medical Products Administration, a Monday bourse filing said.
Pentazocine, which was developed by Sterling Winslip, now Sanofi, in the US and has been registered and China and abroad, is a kind of refined hemp drug use for pain relief, including cancer, traumatic, and postoperative pain.